Dr. Harri Jarvelainen, DVM, PhD, DABT, ERT

Toxicology

25+ years of scientific, managerial, and executive experience in preclinical drug development, toxicology, and clinical development.

Biotech entrepreneur and consultant, advising more than 50 international biotech companies; former senior drug development roles at AstraZeneca and other pharmaceutical companies.

Academic and training background: Degree in Veterinary Medicine and PhD from University Helsinki; postdoctoral training at New York University Medical Center and Max Planck Institute, Berlin; Adjunct Professor of Toxicology, University of Helsinki (since 2004).

Board Certified in Toxicology in both the US (DABT) and Europe (ERT).